According to FutureWise analysis the market for Lung Cancer Liquid Biopsy in 2023 is US$ 0.36 billion, and is expected to reach US$ 1.7 billion by 2031 at a CAGR of 21.22%.
Liquid biopsy plays an integral part in precision medicine, and its diagnostic and treatment implications for oncology are profound, bringing radical changes to clinical practice. By examining a simple blood sample, doctors are able to detect diseases or tumors early on. It is possible to determine the line of treatment which is most likely to work for a patient by looking at the circulation of cancer cells or traces of RNA or DNA from cancer cells in the blood. In addition, liquid biopsies enhance the ability to understand metastatic disease development. A liquid biopsy is used to detect cancer at an early stage. Additionally, it is used for planning a line of treatment for cancer, determining the effectiveness of a line of treatment, and detecting the return of cancer. Multiple samples of blood can be examined with liquid biopsy over a period of time, which allows doctors to understand how molecular changes occur within tumors. Increasing lung cancer incidence is one of the main drivers of the lung cancer liquid biopsy market. The most common type of cancer that causes death worldwide is lung cancer. There are several factors contributing to the increasing prevalence of lung cancer, including smoking, passive smoking, air pollution, and genetic abnormalities. During a liquid biopsy, cancer cells are extracted from a tumor sample and tested on the sample of blood. In the early stages of cancer, liquid biopsy can be used as a diagnostic test. Additionally, it can be used for planning treatments or for assessing how well the treatment is working. In addition, it can be used to check for cancer recurrence. Taking multiple samples of blood over time allows doctors to understand the pattern of molecular changes in a tumor. Lung cancer liquid biopsy market is expected to be positively affected by the application of liquid biopsy for personalized medicine during the forecast period. Global lung cancer liquid biopsy market growth is fuelled by the rise in prevalence, incidence, and awareness of the disease. It is anticipated that technological advancements in imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), will restrain the global lung cancer liquid biopsy market during the forecast period.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Lung Cancer Liquid Biopsy Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Lung Cancer Liquid Biopsy Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.